Core Viewpoint - The recent stock transfer and placement agreement of Ying Sheng Science indicates significant financial activities and capital restructuring within the company, highlighting its strategic focus on debt repayment and operational funding [1] Group 1: Stock Transfer - On September 16, shareholders of Ying Sheng Science transferred shares from Hope Securities to Bank of China (Hong Kong), with a market value of HKD 3.7261 million, accounting for 8.45% of the total shares [1] Group 2: Placement Agreement - On September 11, Ying Sheng Science announced a placement agreement with a placement agent, agreeing to place 30.9515 million new shares at a price of HKD 0.350 per share, representing approximately 16.67% of the enlarged issued share capital post-placement [1] - The total nominal value of the placement shares will be HKD 309,500 [1] - The total proceeds from the placement are estimated to be HKD 10.833 million, with a net amount of approximately HKD 10.32 million after deducting all related expenses [1] Group 3: Use of Proceeds - Approximately 50% of the net proceeds from the placement is intended for loan repayment, while the other 50% is earmarked for the group's working capital and general corporate purposes [1]

瀛晟科学宣布，将按每股0.350港元的价格配售3095.15万股新股份，占配售扩大后总股本的约16.67%。 配售所得款项总额为1083.3万港元，净额约1032万港元，其中约50%将用于偿还贷款，其余用于集团营 运资金及一般企业用途。 ...

Group 1 - The company, Ying Sheng Science (00209), announced a placement agreement with a placement agent to issue 30.9515 million new shares at a price of HKD 0.350 per share, representing approximately 16.67% of the company's total issued shares post-placement [1] - The placement price of HKD 0.350 per share is at a premium of about 1.45% compared to the closing price of HKD 0.345 per share on the date of the placement agreement [1] - The total nominal value of the placement shares will be HKD 30.95 million, with total proceeds estimated at HKD 10.833 million, and the net proceeds after all related expenses are expected to be approximately HKD 10.32 million [1] Group 2 - Approximately 50% of the net proceeds will be used to repay loans, while the remaining 50% will be allocated for the group's working capital and general corporate purposes [1]

智通财经APP讯，瀛晟科学(00209)发布公告，于2025年9月11日(交易时段后)，公司与配售代理订立配 售协议，据此，配售代理同意按悉数包销基准按每股配售股份0.350港元的价格为及代表公司向不少于 六名承配人配售3095.15万股新股份，占经配售事项扩大后公司已发行股份总数约16.67%。配售股份将 根据一般授权配发及发行。 配售价每股配售股份0.350港元较于配售协议日期在联交所所报的收市价每股股份0.345港元溢价约 1.45%。 配售股份的总面值将为30.95万港元。配售事项的所得款项总额将为1083.3万港元。经扣除所有相关开支 后，配售事项的所得款项净额估计约为1032万港元，其约50%拟用作偿还贷款，及约50%拟用作集团营 运资金及一般企业用途。 ...

Core Viewpoint - Ying Sheng Science (00209.HK) announced a placement agreement to issue 30.95 million new shares at a price of HKD 0.350 per share, representing a 1.45% premium over the closing price on the agreement date and a 7.16% discount to the average closing price over the preceding five trading days [1] Group 1: Placement Details - The placement will be fully underwritten by the placement agent and will be made to no fewer than six subscribers [1] - The new shares represent 20% of the existing issued share capital as of the announcement date and approximately 16.67% of the enlarged issued share capital post-placement [1] - The total nominal value of the placement shares will be HKD 30,950 [1] Group 2: Financial Implications - The total proceeds from the placement are estimated to be HKD 10.83 million, with a net amount of approximately HKD 10.32 million after deducting all related expenses [1] - Approximately 50% of the net proceeds will be used to repay loans, and the remaining 50% will be allocated for working capital and general corporate purposes [1]

香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 本公告僅供參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 WINSHINE SCIENCE COMPANY LIMITED 209 根據一般授權配售新股份 配售代理 IMAGI BROKERAGE LIMITED 於二零二五年九月十一日（交易時段後），本公司與配售代理訂立配售協議，據此，配 售代理同意按悉數包銷基準按每股配售股份0.350港元之價格為及代表本公司向不少於 六名承配人配售30,951,496股新股份。配售股份將根據一般授權配發及發行。 配售價每股配售股份0.350港元較：(i)於配售協議日期在聯交所所報之收市價每股股份 0.345港元溢價約1.45%；及(ii)於緊接配售協議日期前五個連續交易日在聯交所所報每 股股份之平均收市價0.377港元折讓約7.16%。 假設於本公告日期與配售事項完成之間，本公司已發行股本將不會發生變動，配售事 項項下之30,951,496股新股份佔於本公告日期本公司現 ...

瀛晟科学发布公告，李忠海先生(李先生)于2025年9月3日透过Hurray Talent(一间由李先生全资拥有的公 司)出售总数为3739.29万股本公司股份(相当于本公司已发行股本约24.16%)予Peak Access(一间由王女士 全资拥有的公司)。出售事项完成后，本公司的主要股东由Hurray Talent变更为Peak Access。 香港联交所最新资料显示，9月5日，瀛晟科学(00209)股东将股票由由希望证券转入中策富汇证券，转 仓市值1804万港元，占比24.80%。 ...

瀛晟科学发布公告，李忠海先生(李先生)于2025年9月3日透过Hurray Talent(一间由李先生全资拥有的公 司)出售总数为3739.29万股本公司股份(相当于本公司已发行股本约24.16%)予Peak Access(一间由王女士 全资拥有的公司)。出售事项完成后，本公司的主要股东由 Hurray Talent变更为Peak Access。 智通财经APP获悉，香港联交所最新资料显示，9月5日，瀛晟科学(00209)股东将股票由由希望证券转入 中策富汇证券，转仓市值1804万港元，占比24.80%。 ...

李先生辞任本公司执行董事，自2025年9月3日起生效; 瀛晟科学(00209)发布公告，李忠海先生(李先生)于2025年9月3日透过Hurray Talent(一间由李先生全资拥 有的公司)出售总数为3739.29万股本公司股份(相当于本公司已发行股本约24.16%)予Peak Access(一间由 王女士全资拥有的公司)。出售事项完成后，本公司的主要股东由Hurray Talent变更为Peak Access; 本公司非执行董事林少鹏先生(林先生)已获委任为提名委员会成员，自2025年9月3日起生效;及 蒋青辉先生(蒋先生)辞任本公司执行董事及董事会主席，亦不再为提名委员会主席，自2025年9月3日起 生效; 王敬渝女士(王女士)已获委任为本公司执行董事及董事会主席，自2025年9月3日起生效; 本公司独立非执行董事黄天莹女士(黄女士)已获委任为提名委员会主席，自2025年9月3日起生效。 ...

Group 1 - The company Ying Sheng Science (00209) announced that Mr. Li Zhonghai sold a total of 37.3929 million shares, representing approximately 24.16% of the company's issued share capital, to Peak Access, a company wholly owned by Ms. Wang [1] - Following the sale, the major shareholder of the company will change from Hurray Talent to Peak Access [1] - Mr. Li resigned as the executive director of the company, effective from September 3, 2025 [1] Group 2 - Mr. Jiang Qinghui also resigned as the executive director and chairman of the board, and will no longer serve as the chairman of the nomination committee, effective from September 3, 2025 [1] - Ms. Wang Jingyu has been appointed as the executive director and chairman of the board, effective from September 3, 2025 [1] - Mr. Lin Shaopeng, a non-executive director of the company, has been appointed as a member of the nomination committee, effective from September 3, 2025 [1] Group 3 - Ms. Huang Tianying, an independent non-executive director, has been appointed as the chairman of the nomination committee, effective from September 3, 2025 [1]